Stand Up To Cancer dream team tackles t-cell lymphoma, focused on CAR-based strategies
(Stand Up To Cancer) A new $8 million SU2C Dream Team is focused on therapies for T-cell lymphoma using CARs to trigger the immune system to attack and destroy cancerous cells led by Helen Heslop, M.D., Baylor College of Medicine, co-led by Gianpietro Dotti, M.D., UNC Chapel Hill: seeking to develop " off the shelf " CAR cells improving availability& lowering cost; identifying biomarkers to track therapy effectiveness; evaluating a novel small molecule which shows potential as a cytoreductive regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2019 Category: Cancer & Oncology Source Type: news
New PET tracer could aid melanoma detection
A new PET tracer designed to target melanin pigment could improve the detection...Read more on AuntMinnie.comRelated Reading:
FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
PET/CT makes case for directing cervical cancer treatment
FLT-PET points toward survival for glioblastoma patients
Extremity PET/CT scans unnecessary for melanoma patients
FDG-PET/CT foretells melanoma therapy response (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 17, 2019 Category: Radiology Source Type: news
Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma
Brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas, according to the multinational phase 3 ECHELON-2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Traci DeVito Source Type: news
ASH: A + CHP Bests CHOP for Peripheral T - Cell Lymphoma
Median progression - free survival improved with A + CHP vs CHOP; similar incidence of adverse events (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news
ASH: A & #43;CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 -- For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news
DWI-MRI may be best for indeterminate lung nodules
Diffusion-weighted MRI (DWI-MRI) offers comparable or even superior diagnostic...Read more on AuntMinnie.comRelated Reading:
MRI shows promise for lung cancer screening
FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
FDG-PET/CT helps stage men with breast cancer, too
PET/CT makes case for directing cervical cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 3, 2018 Category: Radiology Source Type: news
FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma
MONDAY, Nov. 19, 2018 -- The U.S. Food and Drug Administration on Friday expanded approval for the use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2018 Category: Pharmaceuticals Source Type: news
FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The U.S. Food and Drug Administration expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly. (Source: World Pharma News)
Source: World Pharma News - November 19, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves First-Line Adcetris for Peripheral T-Cell Lymphoma
(MedPage Today) -- Added to chemotherapy, drug delayed disease progression by over 2 years (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 16, 2018 Category: American Health Source Type: news
FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot
The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 16, 2018 Category: American Health Source Type: news
Robot arm assists with PET/CT-guided needle biopsies
By combining a robotic arm-assisted needle navigation system with PET/CT, researchers...Read more on AuntMinnie.comRelated Reading:
FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
FDG-PET/CT helps stage men with breast cancer, too
PET/CT key to NIH's tuberculosis research plan
PET/CT makes case for directing cervical cancer treatment
Can deep learning monitor lesions on F-18 NaF PET/CT? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 6, 2018 Category: Radiology Source Type: news
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
PRINCETON, N.J., Oct. 15, 2018 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where t... Biopharmaceuticals, Oncology Soligenix, hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 15, 2018 Category: Pharmaceuticals Source Type: news
FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
Don't expect much help from FDG-PET/CT results in predicting progression-free...Read more on AuntMinnie.comRelated Reading:
FDG-PET/CT helps stage men with breast cancer, too
PET/CT key to NIH's tuberculosis research plan
PET/CT makes case for directing cervical cancer treatment
Prescan tutorial eases patient concerns about PET/CT
Can deep learning monitor lesions on F-18 NaF PET/CT? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 5, 2018 Category: Radiology Source Type: news
